• Aliases: HKI-272, PB272
    • Irreversible pan-EGFR inhibitor that can potentially overcome the acquired resistance of EGFR T790M mutation by targeting a cysteine residue in the ATP-binding pocket of the receptor
    • FDA approved for extended adjuvant therapy in HER-2 positive breast cancer
    • Recommended dose: 240 mg orally daily with food
    • Half-life: 14 hours (range 7–17 hours)
    • Common side effects: Diarrhea, nausea/vomiting, fatigue, anorexia, skin rash, stomatitis
    • Clinical pearls: Recommend to use antidiarrheal prophylaxis with loperamide
    Other topics in Targeted and Immunotherapy Agents